← Ultragenyx Pharmaceutical Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $161.1m | $100.5m | $113.4m | $433.6m | $713.5m | $307.6m | $132.9m | $213.6m | $173.7m | $421.0m | |
| Prepaid Expense and Other Assets, Current | $20.1m | $28.7m | $42.9m | $51.4m | $57.6m | $71.7m | $68.9m | — | $40.3m | $61.0m | |
| Short-term Investments | $219.0m | $134.0m | $346.3m | $321.6m | — | — | — | — | — | — | |
| Inventory, Net | — | $757k | $7.1m | $11.5m | $13.0m | $16.2m | $26.8m | $34.0m | $45.0m | $52.0m | |
| Assets, Current | $401.7m | $269.6m | $522.4m | $851.0m | $1.3b | $856.6m | $883.9m | $732.2m | $817.1m | $951.0m | |
| Property, Plant and Equipment, Net | $17.1m | $21.8m | $20.0m | $44.3m | $73.5m | $141.2m | $259.7m | $290.6m | $265.9m | $244.0m | |
| Goodwill | — | $44.4m | $44.4m | $44.4m | $44.4m | $44.4m | $44.4m | $44.4m | $44.4m | $44.0m | |
| Intangible Assets, Net (Excluding Goodwill) | — | $141.5m | $129.2m | $129.0m | $131.1m | $130.8m | $160.1m | $166.3m | $178.3m | $176.0m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $30.3m | $40.5m | $34.9m | $26.0m | $23.9m | $25.5m | $23.0m | |
| Other Assets, Noncurrent | $1.8m | $1.3m | $3.5m | $3.5m | $8.8m | $20.6m | $16.8m | $57.7m | $62.7m | $60.0m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | — | $5.2m | $12.7m | $32.8m | $23.1m | $28.4m | $40.4m | $73.4m | $121.8m | $158.0m | |
| Accrued Liabilities, Current | $54.6m | $61.4m | $62.5m | $83.2m | $108.5m | $145.6m | $204.7m | $196.5m | $241.0m | $265.0m | |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax | — | — | ($304k) | $159k | $260k | ($1.3m) | ($5.7m) | $1.3m | $1.0m | $0 | |
| Assets | $540.6m | $490.8m | $719.6m | $1.1b | $1.8b | $1.5b | $1.5b | $1.5b | $1.5b | $1.5b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $7.2m | $8.5m | $10.5m | $11.6m | $12.6m | $10.3m | $12.0m | |
| Accounts Payable, Current | $5.4m | $8.9m | $12.3m | $12.9m | $12.9m | $17.1m | $43.3m | $42.1m | $38.8m | $31.0m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $29.8m | $38.5m | $30.5m | $19.8m | $30.6m | $30.0m | $24.0m | |
| Liabilities, Current | $60.3m | $71.0m | $74.7m | $103.3m | $189.6m | $181.4m | $261.2m | $280.4m | $344.2m | $384.0m | |
| Deferred Income Tax Liabilities, Net | — | $31.2m | $31.2m | $33.3m | $33.3m | $33.3m | $31.7m | $30.1m | $30.1m | $30.0m | |
| Other Liabilities, Noncurrent | $6.4m | $5.1m | $4.8m | — | — | $1.0m | $4.8m | $12.2m | $17.1m | $20.0m | |
| Deferred Tax Liabilities, Net | — | $31.2m | $31.2m | $33.3m | $33.3m | $33.3m | $31.7m | $30.1m | $28.7m | $29.0m | |
| Liabilities | $66.7m | $107.3m | $110.7m | $481.7m | $605.2m | $599.8m | $1.2b | $1.2b | $1.2b | $1.6b | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $41k | $44k | $51k | $58k | $67k | $69k | $70k | $82k | $92k | $0 | |
| Additional Paid in Capital | $1.0b | $1.2b | $1.6b | $2.1b | $2.8b | $3.0b | $3.1b | $3.7b | $4.2b | $4.5b | |
| Retained Earnings (Accumulated Deficit) | ($530.5m) | ($832.7m) | ($1.0b) | ($1.4b) | ($1.6b) | ($2.1b) | ($2.8b) | ($3.4b) | ($4.0b) | ($4.5b) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $905k | ($5.7m) | ($633k) | ($147k) | $689k | ($1.4m) | ($6.6m) | $647k | ($643k) | $1.0m | |
| Stockholders' Equity Attributable to Parent | $474.0m | $383.5m | $608.9m | $653.8m | $1.2b | $922.6m | $352.5m | $275.4m | $255.3m | ($80.0m) | |
| Liabilities and Equity | $540.6m | $490.8m | $719.6m | $1.1b | $1.8b | $1.5b | $1.5b | $1.5b | $1.5b | $1.5b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.